Chronic Antidopaminergic Medication Might Affect Amygdala Structure in Patients with Schizophrenia

Background: Recently amygdala enlargement has been reported in patients with schizophrenia like psychosis of epilepsy. The effect of antipsychotic medication on amygdala structure has not been investigated so far. There is theoretical evidence to support the assumption that dopaminergic neurotransmission might affect neuronal plasticity. Methods: In order to analyze the influence of chronic antidopaminergic medication on amygdala structure we compared amygdala volumes in patients with schizophrenia like psychosis of epilepsy (POE) treated with neuroleptic medication (n = 11) to patients with POE not treated with such medication (n = 15), patients with epilepsy alone (n = 24) and healthy control subjects (n = 20). Results: Analyzing our data with a factorial ANOVA approach, we found a significant effect of the factor medication in that patients treated with antipsychotic medication displayed a ”normalization” of the increased amygdala volumes observed in the untreated patient group. Conclusion: This observation supports the assumption that antidopaminergic medication might affect the amygdala structure.

References

• 1 Amaral D G, Price J L, Pitkänen A, Carmichael S T. Anatomical Organisation of the primate amygdaloid complex. In: Aggleton JP, editor The Amygdala: Neurobiological Aspects of Emotion, Memory, and Mental Dysfunction. New York; Wiley-Liss, Inc 1992: 1-66
• 2 Anderson G D, Rebec G V. Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment.  Biol Psychiatry. 1988;  23 497-506
• 3 Bartlett E J, Wolkin A, Brodie J D, Laska E M, Wolf A P, Sanfilipo M. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.  Psychiatry Res. 1991;  40 115-124
• 4 Bradbury A J, Costall B, Domeney A M, Naylor R J. Laterality of dopamine function and neuroleptic action in the amygdala in the rat.  Neuropharmacology. 1985;  24 1163-1170
• 5 Braus D F, Ende G, Weber-Fahr W, Demirakca T, Henn F A. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study.  Pharmacopsychiatry. 2001;  34 251-253
• 6 Cendes F, Andermann F, Gloor P, Evans A, Jones-Gotman M, Watson C, . et al . MRI volumetric measurement of amygdala and hippocampus in temporal lobe epilepsy.  Neurology. 1993;  43 719-725
• 7 Chakos M H, Lieberman J A, Alvir J, Bilder R, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine.  Lancet. 1995;  345(8947) 456-457
• 8 Chakos M H, Shirakawa O, Lieberman J, Lee H, Bilder R, Tamminga C A. Striatal enlargement in rats chronically treated with neuroleptic.  Biol Psychiatry. 1998;  44 675-684
• 9 Gallinat J, Stotz-Ingenlath G, Lang U E, Hegerl U. Panic attacks, spike-wave activity, and limbic dysfunction. A case report.  Pharmacopsychiatry. 2003;  36 123-126
• 10 Harrison P J. The neuropathology of schizophrenia. A critical review of the data and their interpretation.  Brain. 1999;  122(Pt 4) 593-624
• 11 Heimer L. A new anatomical framework for neuropsychiatric disorder and drug abuse.  Am J Psychiatry. 2003;  160 1726-1739
• 12 Hokama H, Shenton M E, Nestor P G, Kikinis R, Levitt J J, Metcalf D, . et al . Caudate, putamen, and globus pallidus volume in schizophrenia: a quantitative MRI study.  Psychiatry Res. 1995;  61 209-229
• 13 Hulshoff Pol H E, Schnack H G, Mandl R C, van Haren N E, Koning H, Collins D L, . et al . Focal gray matter density changes in schizophrenia.  Arch Gen Psychiatry. 2001;  58 1118-1125
• 14 Iosifescu D V, Shenton M E, Warfield S K, Kikinis R, Dengler J, Jolesz F A, . et al . An automated registration algorithm for measuring MRI subcortical brain structures.  Neuroimage. 1997;  6 13-25
• 15 Keshavan M S, Rosenberg D, Sweeney J A, Pettegrew J W. Decreased caudate volume in neuroleptic-naive psychotic patients.  Am J Psychiatry. 1998;  155 774-778
• 16 Kobayashi S, Ogren S O, Ebendal T, Olson L. Dopamine receptor antagonists block nerve growth factor-induced hyperactivity.  Eur J Pharmacol. 1997;  326 1-5
• 17 Lawrie S M, Abukmeil S S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies.  Br J Psychiatry. 1998;  172 110-120
• 18 Loffler W, Kilian R, Toumi M, Angermeyer M C. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.  Pharmacopsychiatry. 2003;  36 105-112
• 19 Pinna A, Morelli M. Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine.  Neuropsychopharmacology. 1999;  21 93-100
• 20 Rajarethinam R, DeQuardo J R, Miedler J, Arndt S, Kirbat R, Brunberg J A,. et al . Hippocampus and amygdala in schizophrenia: assessment of the relationship of neuroanatomy to psychopathology.  Psychiatry Res. 2001;  108 79-87
• 21 Rosenkranz J A, Grace A A. Modulation of basolateral amygdala neuronal firing and afferent drive by dopamine receptor activation in vivo.  J Neurosci. 1999;  19 11 027-11 039
• 22 Scibilia R J, Lachowicz J E, Kilts C D. Topographic nonoverlapping distribution of D1 and D2 dopamine receptors in the amygdaloid nuclear complex of the rat brain.  Synapse. 1992;  11 146-154
• 23 Steel R M, Whalley H C, Miller P ., Best J J, Johnstone E C, Lawrie S M. Structural MRI of the brain in presumed carriers of genes for schizophrenia, their affected and unaffected siblings.  JNNP. 2002;  72 455-458
• 24 Tavcar R, Dernovsek M Z, Zvan V. Choosing antipsychotic maintenance therapy - a naturalistic study.  Pharmacopsychiatry. 2000;  33 66-71
• 25 Tebartz van Elst L, Baeumer D, Lemieux L, Woermann F, Koepp M J, Krishnamoorthy E,. et al . Amygdala abnormalities in psychosis of epilepsy. A magnetic resonance imaging study in patients with temporal lobe epilepsy.  Brain. 2002;  125 140-149
• 26 Tebartz van Elst L, Ebert D, Trimble M R. Hippocampus and amygdala pathology in depression.  Am J Psychiatry. 2001;  158 652-653
• 27 Tebartz van Elst L, Woermann F, Lemieux L, Thompson P J, Trimble M R. Affective aggression in patients with temporal lobe epilepsy - a quantitative magnetic resonance study of the amygdala.  Brain. 2000;  123 234-243
• 28 Tebartz van Elst L, Woermann F G, Lemieux L, Trimble M R. Amygdala enlargement in dysthymia - a volumetric study of patients with temporal lobe epilepsy.  Biol Psychiatry. 1999;  46 1614-1623
• 29 Watson C, Andermann F, Gloor P, Jones-Gotman M, Peters T, Evans A, . et al . Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging.  Neurology. 1992;  42 1743-1750